8-K: Arvinas Submits New Drug Application for Vepdegestrant, a Novel Breast Cancer Treatment, to U.S. FDA

Arvinas, in collaboration with Pfizer, has submitted a New Drug Application to the U.S. FDA for vepdegestrant, a PROTAC ER degrader, for the treatment of ESR1-mutated ER+/HER2advanced or metastatic breast cancer.

Summary

• Arvinas, Inc. announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for vepdegestrant.
• Vepdegestrant is intended for the treatment of patients with ER-positive (ER+)/human epidermal growth factor receptor 2 (HER2)-negative (ER+/HER2-) ESR1-mutated advanced or metastatic breast cancer who have been previously treated with endocrine-based therapy.
• The NDA submission is supported by positive results from the pivotal Phase 3 VERITAC-2 clinical trial (NCT05654623).
• Results from the VERITAC-2 study were recently presented at the 2025 American Society for Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The New England Journal of Medicine.
• Vepdegestrant is an investigational, orally bioavailable PROTAC (PROteolysis TArgeting Chimera) protein degrader designed to specifically target and degrade the estrogen receptor (ER).
• Arvinas is jointly developing vepdegestrant with Pfizer Inc. under a global collaboration agreement established in July 2021, sharing worldwide development costs, commercialization expenses, and profits.
• The FDA previously granted vepdegestrant Fast Track designation as a monotherapy for this indication.
• The VERITAC-2 trial was a global, randomized Phase 3 study evaluating vepdegestrant as a monotherapy compared to fulvestrant, enrolling 624 patients across 25 countries.
• Patients in the trial had previously received treatment with a CDK4/6 inhibitor plus endocrine therapy, with 43% (n=270) having ESR1 mutations detected.
• The primary endpoint of the VERITAC-2 trial was progression-free survival (PFS) in both the ESR1-mutation and intent-to-treat populations, as determined by blinded independent central review, with overall survival (OS) as a key secondary endpoint.

Sentiment

Score: 9

Explanation: The submission of a New Drug Application for a novel drug with positive Phase 3 data and Fast Track designation is a highly positive and de-risking event for a biotechnology company, indicating significant progress towards market approval and potential revenue generation.

Positives

• Submission of a New Drug Application (NDA) to the FDA marks a significant regulatory milestone, bringing vepdegestrant closer to potential market approval.
• The NDA is supported by positive data from the pivotal Phase 3 VERITAC-2 clinical trial, indicating strong efficacy and safety profiles.
• VERITAC-2 results were presented at the prestigious 2025 ASCO Annual Meeting and published in The New England Journal of Medicine, highlighting the significance and quality of the data.
• Vepdegestrant has received Fast Track designation from the FDA, which may expedite the review process.
• The drug is a PROTAC ER degrader, representing a novel mechanism of action that could offer a much-needed new treatment option for patients with ESR1-mutated ER+/HER2advanced or metastatic breast cancer.
• The collaboration with Pfizer Inc. provides significant resources and expertise for development and potential commercialization.

Risks

• Uncertainty regarding whether Arvinas and Pfizer will successfully perform their respective obligations under the collaboration agreement.
• Risks associated with successfully conducting and completing clinical development for vepdegestrant as a monotherapy.
• Uncertainty whether the VERITAC-2 clinical trial will meet the secondary endpoint for overall survival.
• Risks related to expectations regarding the potential clinical benefit of vepdegestrant to patients.
• Uncertainties relating to regulatory applications and related filing and approval timelines, including the risk that any regulatory approvals, if granted, may be subject to significant limitations on use or subject to withdrawal or other adverse actions by the applicable regulatory authority.
• Risk that FDA or other regulatory authorities may require additional information or further studies, or may fail or refuse to approve or may delay approval of vepdegestrant.
• Uncertainty whether Arvinas and Pfizer will be able to obtain marketing approval for and commercialize vepdegestrant and other product candidates on current timelines or at all.
• Arvinas's ability to protect its intellectual property portfolio.
• Arvinas's reliance on third parties for various aspects of its operations.
• Uncertainty whether Arvinas will be able to raise capital when needed.
• Uncertainty whether Arvinas's cash and cash equivalent resources will be sufficient to fund its foreseeable and unforeseeable operating expenses and capital expenditure requirements.

Future Outlook

Arvinas anticipates the FDA's review of the New Drug Application for vepdegestrant and looks forward to the potential availability of the first ever FDA-approved PROTAC ER degrader as a new treatment option for patients with ESR1-mutated ER+/HER2advanced or metastatic breast cancer in the second line-plus setting.

Management Comments

• "This milestone comes after an exciting presentation at the American Society of Clinical Oncologys annual meeting," said John Houston, Ph.D., Chairperson, Chief Executive Officer and President at Arvinas.
• "We look forward to the NDA review and to the first ever FDA-approved PROTAC ER degrader potentially being available to patients who could benefit from a much needed, new treatment option."

Industry Context

The submission of vepdegestrant's NDA represents a significant advancement in the oncology landscape, particularly for breast cancer treatment. As a PROTAC ER degrader, it introduces a novel mechanism of action that could address unmet needs in patients with ESR1 mutations, who often develop resistance to existing endocrine therapies. This positions Arvinas and Pfizer at the forefront of developing next-generation targeted therapies for a challenging patient population.

Stakeholder Impact

• Shareholders: Potential for increased share value due to progress towards market approval and future revenue streams.
• Patients: Access to a potential new, much-needed treatment option for ESR1-mutated ER+/HER2advanced or metastatic breast cancer.
• Employees: Positive impact on morale and potential for growth within the company.
• Partners (Pfizer): Continued collaboration and shared potential for commercial success.
• Healthcare Providers: New therapeutic option to consider for eligible breast cancer patients.

Next Steps

• FDA review of the New Drug Application for vepdegestrant.
• Potential FDA approval of vepdegestrant.
• Potential commercialization of vepdegestrant by Arvinas and Pfizer.

Key Dates

Recommendation

Keywords

Vepdegestrant, Breast Cancer, New Drug Application, FDA, PROTAC, ER Degrader, ESR1 Mutation, Oncology, Clinical Trial, VERITAC-2, Pfizer, Biotechnology, Advanced Breast Cancer, Metastatic Breast Cancer